Patents by Inventor Russell Petter

Russell Petter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2,4-disubstituted pyrimidines as kinase inhibitors
    Patent number: 9409921
    Abstract: The present invention provides 2,4-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: August 9, 2016
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Juswinder Singh, Russell Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20140213574
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: April 16, 2014
    Publication date: July 31, 2014
    Applicant: Celgene Avilomics Research, Inc.
    Inventors: Juswinder Singh, Russell Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • 2,4-disubstituted pyrimidines useful as kinase inhibitors
    Patent number: 8710222
    Abstract: The present invention provides 2,4-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: April 29, 2014
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Juswinder Singh, Russell Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • 2,4-disubstituted pyrimidines useful as kinase inhibitors
    Patent number: 8450335
    Abstract: The present invention provides 2,4-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same. In some embodiments, the present invention provides a compound of formula I-b: wherein each of Ring A, Ring B, W1, W2, Ry, Rv, Rx, m, p, and R1 is described herein.
    Type: Grant
    Filed: June 26, 2009
    Date of Patent: May 28, 2013
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Juswinder Singh, Russell Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • 2,4-disubstituted pyrimidines useful as kinase inhibitors
    Patent number: 8338439
    Abstract: The present invention provides 2,4-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same. In some embodiments, the present invention provides a compound of formula I-a or I-b: wherein each of Ring A, Ring B, W1, W2, Ry, Rv, Rx, m, p, and R1 is described herein.
    Type: Grant
    Filed: December 29, 2009
    Date of Patent: December 25, 2012
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Juswinder Singh, Russell Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20100249092
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: December 29, 2009
    Publication date: September 30, 2010
    Applicant: Avila Therapeutics, Inc.
    Inventors: Juswinder Singh, Russell Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • Transforming Growth Factor Modulators
    Publication number: 20100166819
    Abstract: The invention is related to compounds of formula (I) that can be used as antagonists of the TGF? family type I receptors, Alk5 and/or Alk4, compositions and methods of use. The compounds of formula (I) can be employed in the prevention and/or treatment of diseases such as fibrosis (e.g., renal fibrosis, pulmonary fibrosis, and hepatic fibrosis), progressive cancers, or other diseases for which reduction of TGF? family signaling activity is desirable.
    Type: Application
    Filed: December 22, 2006
    Publication date: July 1, 2010
    Inventors: Wen-Cherng Lee, Lihong Sun, Michael Hoemann, Deqiang Niu, Dingxue Yan, Claudio Chuaqui, Russell Petter, Helen (Xiaomei) Feng
  • Heteroaryl Compounds and Uses Thereof
    Publication number: 20100029610
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: June 26, 2009
    Publication date: February 4, 2010
    Applicant: Avila Therapeutics, Inc.
    Inventors: Juswinder Singh, Russell Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20080004293
    Abstract: The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable.
    Type: Application
    Filed: July 27, 2007
    Publication date: January 3, 2008
    Inventors: Carol Ensinger, James Dowling, Russell Petter, Gnanasambandam Kumaravel
  • Arylphenylamino-,Arylphenylamide-, and Arylphenylether-Sulfide Derivatives
    Publication number: 20070259863
    Abstract: The present invention relates in part to compounds of formulas I and III: and pharmaceutically-acceptable salts and prodrugs thereof. These compounds can be useful for treating diseases such as inflammatory and immune diseases. The present invention also relates to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation or suppressing immune response in a subject.
    Type: Application
    Filed: April 28, 2005
    Publication date: November 8, 2007
    Applicants: ICOS Corporation, Biogen Idec MA Inc.
    Inventors: Donovan Chin, Thomas Durand-Reville, Francine Farouz, Kerry Fowler, Kevin Guckian, Irina Jaconbson, Ramesh Kasar, Russell Petter, Daniel Scott, C. Gregory Sowell, Eugene Thorsett, Edward Yin-Shiang Lin
  • Binding molecules and methods of use thereof
    Publication number: 20070248988
    Abstract: Binding molecules are described.
    Type: Application
    Filed: January 25, 2007
    Publication date: October 25, 2007
    Inventors: Julio Cuervo, Russell Petter, Daniel Scott, Kathryn Strauch
  • A2a adenosine receptor antagonists
    Publication number: 20070173505
    Abstract: The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease. In one embodiment, the invention features a compound of formula (I).
    Type: Application
    Filed: April 9, 2004
    Publication date: July 26, 2007
    Inventors: Hairuo Peng, Gang Yao, Russell Petter, Gnanasambandam Kumaravel
  • Cell adhesion inhibitors
    Publication number: 20070066533
    Abstract: Cell adhesion inhibitors can interact with VLA-4 molecules and inhibits VLA-4 dependent cell adhesion. An inhibitor including a polyethylene glycol moiety can have advantageous pharmaceutical properties.
    Type: Application
    Filed: November 16, 2006
    Publication date: March 22, 2007
    Inventors: Wen-Cherng Lee, R. Pepinsky, Mark Cornebise, Daniel Scott, Russell Petter
  • Adenosine receptor antagonists and methods of making and using the same
    Publication number: 20070015732
    Abstract: The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable.
    Type: Application
    Filed: July 13, 2006
    Publication date: January 18, 2007
    Inventors: William Kiesman, Carol Ensinger, Russell Petter, James Dowling, Gnanasambandam Kumaravel, He Chang, Ko Lin
  • Triazolopyrazines and methods of making and using the same
    Publication number: 20070010520
    Abstract: The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease.
    Type: Application
    Filed: April 9, 2004
    Publication date: January 11, 2007
    Inventors: James Dowling, Gang Yao, Hexi Chang, Hairuo Peng, Jeffrey Vessels, Russell Petter, Gnanasambandam Kumaravel
  • Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists
    Publication number: 20070010522
    Abstract: The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease. In one embodiment, the invention features a compound of formula (I).
    Type: Application
    Filed: April 9, 2004
    Publication date: January 11, 2007
    Inventors: Chi Vu, Russell Petter, Gnanasambandam Kumaravel
  • Pyrazoles and methods of making and using the same
    Publication number: 20060264440
    Abstract: The invention is based on the discovery that compounds of formula I possess unexpectedly high affinity for Alk 5 and/or Alk 4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders. In one embodiment, the invention features a compound of formula I (I).
    Type: Application
    Filed: February 12, 2004
    Publication date: November 23, 2006
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Wen-Cherng Lee, Lihong Sun, Feng Shan, Claudio Chuaqui, Mark Cornebise, Timothy Pontz, Mary Carter, Juswinder Singh, Paula Boriack-Sjodin, Leona Ling, Russell Petter
  • Adenosine receptor antagonists and methods of making and using the same
    Publication number: 20060252730
    Abstract: The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable.
    Type: Application
    Filed: July 10, 2006
    Publication date: November 9, 2006
    Inventors: William Kiesman, Carol Ensinger, Russell Petter, James Dowling, Gnanasambandam Kumaravel, He Xi Chang, Ko Chung Lin
  • Cell adhesion inhibitors
    Publication number: 20060166961
    Abstract: A cell adhesion inhibitor of the general formula: R3-L-L?-R1 is disclosed. An inhibitor of the present invention interacts with VLA-4 molecules and inhibits VLA-4 dependent cell adhesion. Also disclosed are methods for preparing and using such a cell adhesion inhibitor, as well as pharmaceutical compositions containing the same.
    Type: Application
    Filed: February 27, 2006
    Publication date: July 27, 2006
    Applicant: Biogen Idec MA Inc.
    Inventors: Daniel Scott, Wen-Cherng Lee, Russell Petter, Mark Cornebise
  • Tri-substituted heteroaryls and methods of making and using the same
    Publication number: 20060063809
    Abstract: Compounds of formula (I) possess unexpectedly high affinity for Alk 5 and/or Alk 4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders. In one embodiment, the invention features a compound of the general formula (I).
    Type: Application
    Filed: April 4, 2003
    Publication date: March 23, 2006
    Inventors: Wen-Cherng Lee, Lihong Sun, Feng Shan, Claudio Chuaqui, Zhongli Zheng, Russell Petter